Elekta AB stock (SE0000163628): radiation oncology specialist in focus after recent earnings and outlook

Elekta AB, the Swedish specialist for radiation therapy and oncology software, has been back in the spotlight after releasing its latest quarterly results and updating investors on demand trends in its key regions, including North America and Europe. The figures and management commentary offer fresh insights into hospital investment cycles, margin progress and how Elekta is positioning itself against larger medical technology rivals in a competitive global market, according to the company’s investor information and recent earnings materials published in spring 2026 Elekta investor relations as of 04/2026.

The company recently reported results for its fiscal year 2025/26 (Elekta operates on a shifted fiscal year), with management highlighting orders, revenue trends and profitability initiatives, while also commenting on the pipeline for new linear accelerators and software upgrades, based on presentations and releases shared with the capital markets in the first half of 2026 Elekta reports and presentations as of 05/2026.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

Elekta AB: core business model

Elekta AB focuses on solutions that help oncologists and hospitals treat cancer patients with radiation-based therapies and highly specialized software. The group develops and sells linear accelerators for external beam radiation, brachytherapy systems for internal radiation, and planning and information systems that allow clinicians to design and document treatment protocols. These products are typically sold to hospitals, academic centers and private cancer clinics that operate large oncology departments, according to the company’s corporate information Elekta company profile as of 03/2026.

Unlike diversified healthcare conglomerates, Elekta is strongly focused on radiotherapy and oncology IT, which makes its revenue base closely tied to cancer treatment trends, reimbursement frameworks and capital expenditure budgets in healthcare systems. The company’s business model combines one-off equipment sales with long-term service contracts and software licenses, creating a recurring revenue component once machines are installed and treatment software is embedded in clinical workflows. Over the past years, Elekta has also expanded in precision radiotherapy and advanced imaging to support more targeted and adaptive treatments, as highlighted in its technology overview Elekta solutions overview as of 02/2026.

For cancer centers and hospitals, purchasing a radiotherapy system is often a multi-year decision, involving procurement processes, regulatory approvals and financing considerations. Elekta therefore works with long sales cycles and project-based installations. In many cases, the group competes with large players such as Varian (part of Siemens Healthineers) and other regional vendors. The company aims to differentiate through software integration, uptime and service quality, which are crucial for centers that treat high patient volumes and need to minimize downtime of life-saving equipment.

From a financial standpoint, the business model typically involves an initial capital equipment sale, followed by multi-year service and maintenance agreements, upgrades, and, increasingly, subscription-style software revenues. This shift toward a higher share of recurring revenue can help smooth out the inherent volatility of capital equipment ordering cycles. Management has repeatedly emphasized the importance of installed base growth and service attachment rates in its recent investor presentations, pointing to the contribution of services to both revenue stability and margin development Elekta presentations as of 05/2026.

Main revenue and product drivers for Elekta AB

The majority of Elekta AB’s revenue is generated by its Oncology segment, which includes the sale of linear accelerators, oncology information systems and treatment planning software. These systems are used for external beam radiation therapy, a standard modality for many solid tumors. Demand is driven by cancer incidence trends, hospital investment cycles and the replacement of older equipment that no longer meets technical or regulatory standards. Over the years, Elekta has also invested in more advanced systems supporting stereotactic radiosurgery and other high-precision treatments, according to its product descriptions and clinical case studies Elekta radiation therapy solutions as of 01/2026.

Another important area is brachytherapy, which involves placing radioactive sources close to or inside the tumor. Elekta offers systems and applicators used in prostate, gynecological and other cancers. While this product line is smaller in absolute revenue terms compared with linear accelerators, it broadens the company’s portfolio and allows for tailored treatment options in combination with external beam therapy or surgery. In addition, Elekta’s software platforms, including oncology information systems and planning tools, are central to its customer relationships. They help coordinate patient data, scheduling, dose planning and follow-up, making them deeply embedded in clinical workflows once implemented, as highlighted in software-focused materials Elekta software overview as of 03/2026.

Service revenues are a recurring element and include maintenance, repairs, remote monitoring and upgrades. For hospitals, service contracts aim to maximize uptime and keep systems compliant with evolving standards. For Elekta, they create long-term revenue streams and improve visibility, which in turn can support investments in research and development. In recent communications with investors, management has underlined that a growing installed base of equipment, especially in North America and Europe, leads to increasing service income over time, which can help mitigate cyclical swings in new orders and provide a buffer during periods of constrained hospital capital budgets Elekta investor update as of 04/2026.

Geographically, Europe and North America are key markets, but Elekta also targets growth in emerging regions such as Asia, Latin America and parts of the Middle East and Africa. In many of these countries, the number of radiotherapy machines per million inhabitants remains below levels seen in developed healthcare systems, pointing to a potential structural need for new installations over time. However, execution in these markets often depends on public funding, import regulations and local partnerships. Elekta’s revenue mix therefore reflects both mature markets with a strong replacement cycle and developing markets with a more pronounced need for first-time installations.

Industry trends and competitive position

The global radiation oncology market is shaped by several structural trends, including an aging population, increasing cancer incidence and the push for more precise, less invasive treatments. In many countries, policymakers also emphasize value-based care and improved patient outcomes, which puts pressure on hospitals to invest in technologies that can deliver accuracy while minimizing side effects. Elekta AB operates in this environment alongside major competitors in radiotherapy and imaging. The company’s positioning is influenced by its focus on software integration and adaptive therapy, areas that management sees as differentiation points, according to its strategy presentations Elekta strategy materials as of 05/2026.

Across the industry, hospital procurement decisions increasingly consider total cost of ownership, including energy use, maintenance and uptime. This can benefit vendors that demonstrate robust service networks and advanced monitoring capabilities. At the same time, budget pressures in publicly funded health systems and uncertainties around reimbursement can delay or reduce spending on new equipment. Elekta has acknowledged such dynamics in recent earnings updates, noting that while long-term demand fundamentals remain supported by demographics and clinical needs, quarterly order intake can still be influenced by project timing and administrative processes in key markets Elekta earnings commentary as of 04/2026.

In terms of technology, the move toward image-guided and adaptive radiotherapy requires integration of imaging, planning and delivery solutions. Elekta has invested in systems that can adjust treatment based on changes in patient anatomy or tumor size, aiming to improve precision and spare healthy tissue. This direction also drives demand for advanced software, data analytics and potentially cloud-based workflows. For investors, the pace at which Elekta can develop and commercialize such technologies, while maintaining reliability and regulatory compliance, is a key factor in its competitive standing relative to larger peers and emerging niche players.

Why Elekta AB matters for US investors

Although Elekta AB is headquartered in Sweden and listed on Nasdaq Stockholm, its products are used in many US hospitals and cancer centers. This means the company’s performance is partly linked to US healthcare investment cycles, reimbursement frameworks for radiation oncology, and trends in cancer treatment protocols. For US-based investors who follow global medical technology names, Elekta offers exposure to a specialized segment of oncology equipment and software that differs from broader diversified healthcare firms. The company’s presence in the US also reflects regulatory approvals and clinical adoption in one of the world’s largest healthcare markets, as indicated in Elekta’s references to installations in North America Elekta solutions overview as of 02/2026.

From a portfolio perspective, Elekta can be seen in the context of other listed medtech and oncology companies, including US-based manufacturers of imaging systems, surgical robots and pharmaceutical therapies. Movements in the stock may therefore react to sector-wide news, such as changes in US reimbursement for radiotherapy, shifts in oncology treatment guidelines, or macroeconomic factors that influence hospital capital expenditure. Additionally, currency fluctuations between the Swedish krona and the US dollar can play a role for US investors, both because Elekta reports in SEK and because part of its cost and revenue base is denominated in other currencies. Such factors are often discussed in the company’s financial reports alongside regional revenue breakdowns Elekta financial reports as of 05/2026.

For US institutions that benchmark against global healthcare indices, Elekta’s stock can influence sector allocations, particularly within specialized medtech and oncology equipment segments. While the company does not trade directly on a US exchange in its primary listing, it may still be accessible through international trading arrangements or funds that hold Swedish equities. As with any foreign investment, investors monitoring Elekta’s developments typically consider both company-specific factors and broader macro and regulatory themes in its core markets.

Conclusion

Elekta AB remains a focused player in radiation oncology, combining capital equipment, software and services targeted at cancer centers worldwide. Recent earnings and outlook updates underline how order intake, service growth and regional dynamics shape the company’s trajectory, while also highlighting ongoing investments in precision and adaptive radiotherapy technologies, according to its latest investor communications Elekta investor information as of 04/2026. For investors, the stock sits at the intersection of long-term demographic trends supporting cancer care demand and shorter-term variables such as hospital budgets, competitive developments and currency movements. The balance between equipment sales and recurring service and software revenues, along with execution on the company’s strategic initiatives, will likely remain central themes in market discussions around Elekta’s equity story.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.